Lilly wraps up acquisition of Versanis, marking the fifth largest pharma deal of 2023

Top 5 biggest M&A deals in the pharmaceutical industry as of August 14, 2023: Pfizer/Seagen ($43B), Biogen/Reata Pharmaceuticals ($7.3B), Astellas Pharma/Iveric Bio ($5.9B), Merck & Co./Prometheus Biosciences ($10.8B), Eli Lilly/Versanis ($1.93B).

Eli Lilly just wrapped up its acquisition of Versanis Bio in a $1.9 billion deal, the pharma giant announced today. The deal marks Lilly’s latest move to build up its pipeline of potential obesity and diabetes treatments, which promises to be a notable growth area for the company. Lilly recently completed its submission of tirzepatide for chronic weight management to the FDA.

The company reported positive Phase 3 results from the SURMOUNT-3 and SURMOUNT-4 studies, showing the highest levels of weight loss observed so far in the SURMOUNT program.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1…

Read more
  • 0

The top 10 pharma M&A deals of 2022

[Photo by John Guccione via Pexels]: 

2022 was a shaky year for M&A deals in the pharmaceutical and life sciences sector, as PwC recently surmised. That’s not surprising, given the recession fears and inflation themes common throughout the year.

That said, Amgen (Nasdaq:AMGN) and Pfizer bucked the trend by spending 11-figure sums on M&A deals. Bristol Myers Squibb, Biocon Biologics and GSK also had sizeable acquisitions.

Here are ten M&A deals in 2022 worth at least $1 billion.

1. Amgen to pay $27.8 billion for Horizon Therapeutics

Amgen agreed to pay $116.50 per share for Horizon Therapeutics (Nasdaq:HZNP) for a total of $27.8 billion, marking the biggest biopharma deal of the year. In 2021, Horizon had $3.23 billion in revenue, marking a 47% increase over the previous year. Horizon also discussed a potential acquisition deal with Janssen Global Services and Sanofi before deciding to m…

Read more
  • 0